Health
Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura – News-Medical.net
In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP)…
In a new study by Yale Cancer Center (YCC) researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care. The findings are being presented today at the virtual 62nd American Society of Hematology (ASH) Annual Meeting & Exposition.
We performed the first-ever cost effectiveness analysis in acquired TTP and found that the addition of caplacizumab to standard of care treatment is not cost effective at its…
Continue Reading